Skip to main content
Erschienen in:

01.02.2007 | Leitthema

Radiochemotherapie als Behandlungsstandard fortgeschrittener Kopf-Hals-Karzinome

verfasst von: Dr. R. Semrau, R. Fietkau, J.A. Werner, R.-P. Mueller

Erschienen in: Die Onkologie | Ausgabe 2/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Gegenüber einer alleinigen Bestrahlung von fortgeschrittenen inoperablen Kopf-Hals-Tumoren kann eine simultane Radiochemotherapie die lokoregionäre Tumorkontrolle und das Überleben der Patienten verbessern. Heute liegt dazu eine Vielzahl randomisierter multizentrischer Phase-III-Studien mit verschiedenen Fraktionierungsschemata vor. Intensivierte Bestrahlungsprotokolle sowie der Einsatz von Taxanen erhöhen die Effektivität, aber auch die akute Therapietoxizität. Vor diesem Hintergrund sind das optimale Fraktionierungsschema sowie die optimale Substanzkombination Gegenstand aktueller wissenschaftlicher Untersuchungen. Die neoadjuvante Chemotherapie kann nicht als Behandlungsstandard angesehen werden.
Literatur
1.
Zurück zum Zitat Abitbol A, Abdel-Wahab M, Harvey M et al. (2005) Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol. Am J Clin Oncol 28: 449–455CrossRefPubMed Abitbol A, Abdel-Wahab M, Harvey M et al. (2005) Phase II study of tolerance and efficacy of hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (taxol) and amifostine (ethyol) in head and neck squamous cell carcinomas: A-3 protocol. Am J Clin Oncol 28: 449–455CrossRefPubMed
2.
Zurück zum Zitat Adelstein D J, Li Y, Adams GL et al. (2003) An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer. J Clin Oncol 21: 92–98CrossRef Adelstein D J, Li Y, Adams GL et al. (2003) An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer. J Clin Oncol 21: 92–98CrossRef
3.
Zurück zum Zitat Aguilar-Ponce J, Granados-Garcia M, Villavicencio V et al. (2004) Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 15: 301–306CrossRefPubMed Aguilar-Ponce J, Granados-Garcia M, Villavicencio V et al. (2004) Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 15: 301–306CrossRefPubMed
4.
Zurück zum Zitat Bensadoun RJ, Benezery K, Dassonville O et al. (2006) French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 64: 983–994CrossRefPubMed Bensadoun RJ, Benezery K, Dassonville O et al. (2006) French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: Results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 64: 983–994CrossRefPubMed
5.
Zurück zum Zitat Bonner J A, Harari P M, Giralt J et al. (2006) Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 354: 567–578CrossRefPubMed Bonner J A, Harari P M, Giralt J et al. (2006) Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 354: 567–578CrossRefPubMed
6.
Zurück zum Zitat Bourhis J, Amand C, Pignon JP (2004) Update of MACH-NC (Meta-analysis of chemotherapy in head & neck cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 23, ASCO Annual Meeting Procedures, Abstr 5505 Bourhis J, Amand C, Pignon JP (2004) Update of MACH-NC (Meta-analysis of chemotherapy in head & neck cancer) database focused on concomitant chemoradiotherapy. J Clin Oncol 23, ASCO Annual Meeting Procedures, Abstr 5505
7.
Zurück zum Zitat Bourhis J, Overgaard J, Audry H et al. (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368: 843–854CrossRefPubMed Bourhis J, Overgaard J, Audry H et al. (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368: 843–854CrossRefPubMed
8.
Zurück zum Zitat Brizel DM, Albers ME, Fisher SR et al. (1998) Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer. N Engl J Med 338: 1798–1804CrossRefPubMed Brizel DM, Albers ME, Fisher SR et al. (1998) Hyperfractionated Irradiation with or without Concurrent Chemotherapy for Locally Advanced Head and Neck Cancer. N Engl J Med 338: 1798–1804CrossRefPubMed
9.
Zurück zum Zitat Budach V, Stuschke M, Budach W et al. (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95–06 Prospective Randomized Trial. J Clin Oncol 23: 1125–1135CrossRefPubMed Budach V, Stuschke M, Budach W et al. (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95–06 Prospective Randomized Trial. J Clin Oncol 23: 1125–1135CrossRefPubMed
10.
Zurück zum Zitat Budach W, Hehr T, Budach V et al. (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6: 28CrossRefPubMed Budach W, Hehr T, Budach V et al. (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6: 28CrossRefPubMed
11.
Zurück zum Zitat Calais G, Alfonsi M, Bardet E et al. (1999) Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91: 2081–2086CrossRefPubMed Calais G, Alfonsi M, Bardet E et al. (1999) Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91: 2081–2086CrossRefPubMed
12.
Zurück zum Zitat Denis F, Garaud P, Bardet E et al. (2004) Final Results of the 94–01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx Carcinoma. J Clin Oncol 22: 69–76CrossRefPubMed Denis F, Garaud P, Bardet E et al. (2004) Final Results of the 94–01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx Carcinoma. J Clin Oncol 22: 69–76CrossRefPubMed
13.
Zurück zum Zitat Domenge C, Hill C, Lefebvre JL et al. (2000) Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83: 1594–1598CrossRefPubMed Domenge C, Hill C, Lefebvre JL et al. (2000) Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83: 1594–1598CrossRefPubMed
14.
Zurück zum Zitat Fu KK, Pajak TF, Trotti A et al. (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48: 7–16PubMed Fu KK, Pajak TF, Trotti A et al. (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48: 7–16PubMed
15.
Zurück zum Zitat Garden AS, Harris J, Vokes EE et al. (2004) Preliminary results of Radiation Therapy Oncology Group 97–03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22: 2856–2864CrossRefPubMed Garden AS, Harris J, Vokes EE et al. (2004) Preliminary results of Radiation Therapy Oncology Group 97–03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. J Clin Oncol 22: 2856–2864CrossRefPubMed
16.
Zurück zum Zitat Horiot JC, Bontemps P, Van den Bogaert W et al. (1997) Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44: 111–121CrossRefPubMed Horiot JC, Bontemps P, Van den Bogaert W et al. (1997) Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. Radiother Oncol 44: 111–121CrossRefPubMed
17.
Zurück zum Zitat Horiot JC, Le Fur R, N’Guyen T et al. (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25: 231–241CrossRefPubMed Horiot JC, Le Fur R, N’Guyen T et al. (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25: 231–241CrossRefPubMed
18.
Zurück zum Zitat Huguenin P, Beer KT, Allal A et al. (2004) Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy. J Clin Oncol 22: 4613–4621CrossRefPubMed Huguenin P, Beer KT, Allal A et al. (2004) Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated With Hyperfractionated Radiotherapy. J Clin Oncol 22: 4613–4621CrossRefPubMed
19.
Zurück zum Zitat Kuhnt T, Becker A, Pigorsch S et al. (2003) Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Strahlenther Onkol 179: 673–681CrossRefPubMed Kuhnt T, Becker A, Pigorsch S et al. (2003) Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial. Strahlenther Onkol 179: 673–681CrossRefPubMed
20.
Zurück zum Zitat Lovey J, Koronczay K, Remenar E et al. (2003) Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radiother Oncol 68: 171–174CrossRefPubMed Lovey J, Koronczay K, Remenar E et al. (2003) Radiotherapy and concurrent low-dose paclitaxel in locally advanced head and neck cancer. Radiother Oncol 68: 171–174CrossRefPubMed
21.
Zurück zum Zitat Merlano M, Russi EG, Numico G et al. (2005) Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial. Radiother Oncol 75: 193–196CrossRefPubMed Merlano M, Russi EG, Numico G et al. (2005) Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial. Radiother Oncol 75: 193–196CrossRefPubMed
22.
Zurück zum Zitat Milano MT, Haraf DJ, Stenson KM et al. (2004) Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck. Clin Cancer Res 10: 4922–4932CrossRefPubMed Milano MT, Haraf DJ, Stenson KM et al. (2004) Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck. Clin Cancer Res 10: 4922–4932CrossRefPubMed
23.
Zurück zum Zitat Paccagnella A, Orlando A, Marchiori C et al. (1994) Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86: 265–272CrossRefPubMed Paccagnella A, Orlando A, Marchiori C et al. (1994) Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86: 265–272CrossRefPubMed
24.
Zurück zum Zitat Pignon JP, Bourhis J, Domenge C et al. (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949–955PubMed Pignon JP, Bourhis J, Domenge C et al. (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949–955PubMed
25.
Zurück zum Zitat Posner MR, Hershock D, Le Lann L et al. (2006) TAX 324: A Phase III Trial of TPF vs. PF Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced SCCHN. ASCO Annual Meeting Abstracts 2006 Posner MR, Hershock D, Le Lann L et al. (2006) TAX 324: A Phase III Trial of TPF vs. PF Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced SCCHN. ASCO Annual Meeting Abstracts 2006
26.
Zurück zum Zitat Rosen FR, Haraf DJ, Kies MS et al. (2003) Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 9: 1689–1697PubMed Rosen FR, Haraf DJ, Kies MS et al. (2003) Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res 9: 1689–1697PubMed
27.
Zurück zum Zitat Semrau R, Mueller RP, Stuetzer H et al. (2006) Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 64: 1308–1316CrossRefPubMed Semrau R, Mueller RP, Stuetzer H et al. (2006) Efficacy of intensified hyperfractionated and accelerated radiotherapy and concurrent chemotherapy with carboplatin and 5-fluorouracil: updated results of a randomized multicentric trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 64: 1308–1316CrossRefPubMed
28.
Zurück zum Zitat Staar S, Rudat V, Stuetzer H et al. (2001) Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy – results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50: 1161–1171CrossRefPubMed Staar S, Rudat V, Stuetzer H et al. (2001) Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy – results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50: 1161–1171CrossRefPubMed
29.
Zurück zum Zitat Suntharalingam M, Haas ML, Van Echo DA et al. (2001) Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 91: 548–554CrossRefPubMed Suntharalingam M, Haas ML, Van Echo DA et al. (2001) Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neck. Cancer 91: 548–554CrossRefPubMed
30.
Zurück zum Zitat Sunwoo JB, Herscher LL, Kroog GS et al. (2001) Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 19: 800–811PubMed Sunwoo JB, Herscher LL, Kroog GS et al. (2001) Concurrent paclitaxel and radiation in the treatment of locally advanced head and neck cancer. J Clin Oncol 19: 800–811PubMed
31.
Zurück zum Zitat Vermorken JB, Remenar E, Van Herpen C et al. (2004) Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). J Clin Oncol 22: 5508 Vermorken JB, Remenar E, Van Herpen C et al. (2004) Standard cisplatin/infusional 5-fluorouracil (PF) vs docetaxel (T) plus PF (TPF) as neoadjuvant chemotherapy for nonresectable locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): A phase III trial of the EORTC Head and Neck Cancer Group (EORTC #24971). J Clin Oncol 22: 5508
32.
Zurück zum Zitat Wendt TG, Grabenbauer GG, Rodel CM et al. (1998) Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16: 1318–1324 Wendt TG, Grabenbauer GG, Rodel CM et al. (1998) Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16: 1318–1324
Metadaten
Titel
Radiochemotherapie als Behandlungsstandard fortgeschrittener Kopf-Hals-Karzinome
verfasst von
Dr. R. Semrau
R. Fietkau
J.A. Werner
R.-P. Mueller
Publikationsdatum
01.02.2007
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 2/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-006-1161-0

Weitere Artikel der Ausgabe 2/2007

Der Onkologe 2/2007 Zur Ausgabe

CME Weiterbildung • Zertifizierte Fortbildung

Psychoonkologie

Neu im Fachgebiet Onkologie

Muskeln trainieren gegen Nervenschäden durch Chemotherapie

17.07.2024 Nebenwirkungen der Krebstherapie Nachrichten

Chemotherapien können die Nerven schädigen und damit die Lebensqualität von Betroffenen zusätzlich einschränken. Wer aber auf die richtige Art trainiert, kann das absolute Risiko für Neuropathien um bis zu 40% senken.

Die beste Jahreszeit für eine Krebsimmuntherapie

16.07.2024 Onkologische Immuntherapie Nachrichten

Schon länger ist bekannt, dass die Aktivität des Immunsystems mit den Jahreszeiten variiert. Auch die Wirksamkeit von Checkpointhemmern scheint klinisch relevanten saisonalen Schwankungen zu unterliegen, wie eine Studie bei fortgeschrittenem nichtkleinzelligem Lungenkarzinom zeigt.

Partielle Nephrektomie: Videoanalysen zur Verbesserung der chirurgischen Qualität

16.07.2024 Nephrektomie Nachrichten

Je versierter Operateurinnen und Operateure sind, desto geringer ist das Risiko für Komplikationen. Eine kleine US-Studie spricht dafür, dass das auch bei Roboter-assistierten Nephrektomien gilt – und dass sich Op.-Videos für die Beurteilung eignen.        

S3-Leitlinie Endometriumkarzinom aktualisiert

15.07.2024 Endometriumkarzinom Nachrichten

Die angepasste Version der S3-Leitlinie Endometriumkarzinom enthält unter anderem Empfehlungen zu Risikofaktoren, wie der Hormonersatztherapie, sowie darüber, wann eine vaginale Brachytherapie und wann eine Perkutanbestrahlung angebracht ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.